Company intelligence / Profile preview

Ina Hawaii

Honolulu, Hawaii, United Statespainahawaii.com ↗

Ownership: Private
Development stage: Other

Overview

Hawaii Biotech has advanced a recombinant subunit vaccine for West Nile Virus into Phase 1 clinical trials and has developed additional vaccine candidates for dengue, tick-borne encephalitis, influenza, malaria, Ebola, and Zika. The company’s Drosophila S2 cell-based protein production platform supports rapid development of new vaccines. Early clinical results from the West Nile program indicated good safety and immunogenicity in healthy volunteers[4][5][6].

Therapeutic areas: Infectious Diseases
Modalities: Recombinant proteinVaccine
Industry: Biotech

Beyond the preview

Go deeper on Ina Hawaii.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ina Hawaii.

Explore the full profile